A new treatment for autoimmune blistering diseases - the efficacy of the Bruton’s tyrosine kinase inhibitor PRN473 in canine pemphigus foliaceus - 21/04/16
Catherine Outerbridge, DVM, University of California, Davis, Davis, CA, United States; Stephen White, DVM, PhD, University of California School of Veterinary Medicine’s Veterinary Medical Teaching Hospital, Davis, CA, United States; Katarina Varjonen, DVM, University of California School of Veterinary Medicine’s Veterinary Medical Teaching Hospital, Davis, CA, United States; Elizabeth Goodale, DVM, University of California School of Veterinary Medicine’s Veterinary Medical Teaching Hospital, Davis, CA, United States; Dori Borjesson, DVM, PhD, University of California School of Veterinary Medicine’s Veterinary Medical Teaching Hospital, Davis, CA, United States; Dedee Murrell, MD, St Georges Hospital, Kogarah, Australia; Angelina Bisconte, Principia Biopharma Inc, South San Francisco, CA, United States; Ronald Hill, PhD, Principia Biopharma Inc, South San Francisco, CA, United States; Mohammad Masjedizadeh, PhD, Principia Biopharma Inc, South San Francisco, CA, United States; Steven Gourlay, MBBS, PhD, Principia Biopharma Inc, South San Francisco, CA, United States
Le texte complet de cet article est disponible en PDF. Supported and fully paid for by Principia Biopharma Inc. |
Vol 74 - N° 5S1
P. AB141 - mai 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?